Kewalramani becme the first female CEO of a large, public U.S. biotechnology company after immigrating from India at age 11 ...

TIME magazine has released the list of the 100 Most Influential People of 2025 and Reshma Kewalramani, Indian-origin CEO, is ...

From US president Donald Trump to Tesla CEO Elon Musk, Time Magazine's 100 Most Influential People of 2025 list included some ...

The most recent trading session ended with Ginkgo Bioworks Holdings, Inc. (DNA) standing at $8.09, reflecting a -1.94% shift from the previouse trading day's closing. This change was narrower than the ...

Born in Mumbai, Reshma moved to the United States in 1988. She pursued a career in medicine, earning her degree from Boston ...

Trained in internal medicine and nephrology, Reshma once intended to teach, treat patients, and work in a lab after medical ...

The Global Synthetic Biology Market is valued at USD 16.94 Billion in 2024 and is projected to reach a value of USD 167.98 ...

Reshma is the kind of leader who can deliver that extraordinary future—it only seems crazy because no one’s done it before. I ...

The Synthetic Biology Market is valued at USD 16.94 Billion in 2024 and is expected to reach USD 167.98 Billion by 2035 at a ...

FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.

AI-driven drug discovery firms rallied on Friday after the U.S. Food and Drug Administration (FDA) announced an initiative to ...

Certara’s AI strategy and FDA-aligned offerings fuel growth across drug discovery and trials, with expanding margins. Read ...